Sutro Biopharma (STRO) Annual Income Statement (USD)
STRO Quarterly Financials (USD)
Frequently Asked Questions About Sutro Biopharma (STRO) Stock
Sutro Biopharma's (STRO) last reported annual revenue was USD 153.73 Million.
Sutro Biopharma's (STRO) annual revenue growth rate based on the revenue reported in the past 5 years is : 31.96%
Sutro Biopharma's(STRO) is not profitable as of its last reported annual financials.
The net profit margin for Sutro Biopharma's(STRO) from its laster reported year is -69.47%
The return on equity (ROE) for Sutro Biopharma's(STRO) from its last reported annual financials is : -110.89%
The return on assets (ROA) for Sutro Biopharma's(STRO) from its last reported annual financials is : -18.40%
The return on invested capital (ROIC) for Sutro Biopharma's(STRO) from its last reported annual financials is : -55.54%
The Debt to Equity ratio for Sutro Biopharma's(STRO) from its last reported annual financials is : 0.00%
The dividend yield for Sutro Biopharma's(STRO) from its laster reported year is 0.00%
Sutro Biopharma's(STRO) has negative cash flow as of its last reported annual financials.
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
Superior return on assets
The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.
High Gross Profit to Asset Ratio
This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.
What not to like
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for STRO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
